The research report "Booming US Generic Drug Market" is an exhaustive analysis of the US generic market. The report does a thorough investigation of both the drivers as well as restraints impacting the market, and the factors that distinguish the US from other generic markets of the world.
The US represents the world's largest market for generic drugs with unbranded generics accounting for more than 50% prescriptions and 10% sales out of the total pharmaceutical market in 2006. The market is driven by several factors, including lower costs, a favorable political environment, and rapidly increasing ageing population.
The top 10 players in the US presently occupy more than 70% of the generic market, with Teva, Sandoz (Novartis) and Mylan leading the market. However, the huge potential and growth of this market is also attracting several Asian and Eastern European players. Thus, competition in this market is expected to heat up in future making the market extremely price sensitive.
Although several challenges, such as price erosion and litigations from branded manufacturers, may hamper growth, the overall growth prospects of the market are good. The market is expected to get a strong boost with the patent expiry of several blockbuster drugs in the next five years and also with the launch of biogenerics (expected in around 2010). Overall, the unbranded generic market is expected to continue its double-digit growth rate between 2007 and 2011 and generate revenues worth more than US$ 69 Billion by 2011.
Key Findings
- Unbranded generics grew faster than branded drugs, biotech drugs and branded generics between 2004 and 2006.
- The sales volume of drugs in the pharmaceutical market is being driven strongly by the sale of generics.
- The Hatchman-Waxman Act was a major boost to the generic business in the US.
- The patent expiry of key biotech drugs is creating opportunities for biogenerics.
- Generic substitution of branded drugs resulted in estimated savings of US$ 10.2 Billion in the US in 2006.
- Unbranded generics are expected to occupy more than 19% of the US pharmaceutical market by 2011.
Key Issues & Facts Analyzed
- Evaluation of past, current and future market trends
- Discussion about the size and growth of the market
- Market evaluation by segments
- Analysis of healthcare indicators
- Future prospects of the generic market
- Analysis of various challenges and opportunities for the industry
- Profile discussion of key players in this sector
Key Players Analyzed
This section provides the overview, key facts, and financial information of prominent players in the US generic market, such as Teva Pharmaceutical Industries Limited, Sandoz Inc., Mylan Laboratories Inc., Watson Pharmaceuticals, Inc. and Actavis Group hf.
Research Methodology Used
Information Sources: Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Method: The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.
Table of Contents
Section 1 Analyst View
Section 2 Global Generic Drugs Market
2.1 Market Size & Growth
2.2 By Region
Section 3 United States Generic Drugs Market
3.1 Most Potential Generic Drugs Market
3.2 Market Size & Growth
3.2.1 Pharmaceutical Market
3.2.1.1 By Therapeutic Category
3.2.1.2 By Drugs Category
3.2.1.2.1 Branded Drugs
3.2.1.2.2 Branded Generics
3.2.1.2.3 Unbranded Generics
3.2.1.3 Unbranded Generics witnessing Fastest Growth
Section 4 Regulatory Environment
4.1 Drug Efficacy Study Implementation (DESI) Program
4.2 Hatch-Waxman Act
4.3 Patent Infringement Litigations
4.4 Para IV & the 180-day Marketing Exclusivity
4.5 FDA Requirements
4.6 Generic Initiative for Value & Efficiency (GIVE)
Section 5 Industry Analysis
5.1 Driving Forces
5.1.1 Huge Cost Savings
5.1.2 Patent Expiries
5.1.3 Favorable Political Environment
5.1.4 Ageing Population
5.1.5 Large Uninsured Population
5.1.6 Obesity
5.2 Opportunities
5.2.1 Patent Expiry of Key Drugs
5.2.2 Biogenerics
5.2.3 Contract Manufacturing
5.2.4 Drugs Packaging
5.2.5 Drugs Delivery
5.3 Challenges
5.3.1 Lawsuits
5.3.2 High Entry Barriers
5.3.3 Price Erosion & Depleting Margins
5.3.4 Authorized Generics
Section 6 Future Outlook, 2007-2011
6.1 Driving & Restraining Forces
6.2 Sales
Section 7 Competitive Landscape
7.1 Market Share of Key Players
7.2 Profile of Key Players
7.2.1 Teva Pharmaceutical Industries Limited
7.2.2 Watson Pharmaceuticals, Inc.
7.2.3 Mylan Laboratories Inc.
7.2.4 Sandoz Inc.
7.2.5 Actavis Group hf
Section 8 Supporting Databases
8.1 Macroeconomic Indicators
8.2 Population
8.3 Demographics
8.4 Healthcare Expenditure
8.5 Healthcare Infrastructure
8.6 Major Causes of Mortality
Figures
Figure 2-1: Global - Generic Drugs Market (in Billion US$), 2006 & 2010F
Figure 2-2: Global - Pharmaceutical Market (in Billion US$), 1999-2006
Figure 2-3: Global - Unbranded Generic Drugs Market (in Billion US$), 2001-2006 & 2010F
Figure 2-4: Global - Share of Unbranded & Branded Generics in Generic Drugs Market (%), 2006 & 2010F
Figure 2-5: Global - Breakup of Unbranded Generic Drugs Market by Region (%), 2006
Figure 3-1: Global - Top Unbranded Generic Drugs Market (in Billion US$), 2006
Figure 3-2: Global - Top Pharmaceutical Markets (in Billion US$), 2006
Figure 3-3: Global - Per Capita Drugs Consumption of Top Pharmaceutical Markets (in US$), 2006
Figure 3-4: US - Number of Prescriptions for Pharmaceutical Market (in Billion), 2004-2006
Figure 3-5: US - Pharmaceutical Market (in Billion US$), 2002-2006
Figure 3-6: US - Prescriptions Breakup for Pharmaceutical Market by Drug Category (%), 2006
Figure 3-7: US - Sales Breakup of Pharmaceutical Market by Drug Category (%), 2006
Figure 3-8: US - Share of Prescriptions for Branded Drugs in Pharmaceutical Prescriptions (%), 2002-2006
Figure 3-9: US - Number of Prescriptions for Branded Drugs (in Billion), 2005 & 2006
Figure 3-10: US - Share of Branded Drugs Sales in Pharmaceutical Market (%), 2002-2006
Figure 3-11: US - Branded Drugs Market (in Billion US$), 2002-2006
Figure 3-12: US - Share of Prescriptions for Branded Generic Drugs in Pharmaceutical Prescriptions (%), 2002-2006
Figure 3-13: US - Number of Prescriptions for Branded Generic Drugs (in Billion), 2005 & 2006
Figure 3-14: US - Share of Branded Generic Drugs Sales in Pharmaceutical Market (%), 2002-2006
Figure 3-15: US - Branded Generic Drugs Market (in Billion US$), 2002-2006
Figure 3-16: US - Share of Prescriptions for Unbranded Generic Drugs in Pharmaceutical Prescriptions (%), 2002-2006
Figure 3-17: US - Number of Prescriptions for Unbranded Generic Drugs (in Billion), 2005 & 2006
Figure 3-18: US - Share of Unbranded Generic Drugs Sales in Pharmaceutical Market (%), 2002-2006
Figure 3-19: US - Unbranded Generic Drugs Market (in Billion US$), 2002-2006
Figure 3-20: US - Breakup of Unbranded Generic Drugs by Formulation Type (%), 2005
Figure 3-21: US - Sales Growth of Various Pharmaceutical Sectors (%), 2003-2006
Figure 3-22: US - Share of Branded, Branded Generics & Unbranded Generics in Growth of Pharmaceutical Market (%), 2006
Figure 4-1: US - Generic Drugs Approval Process
Figure 4-2: US - Median Approval Time for ANDA Originals (in Months), 2000-2006
Figure 5-1: US - Product Development Time for Generic & Branded Pharmaceuticals (in Years)
Figure 5-2: US - Average Retail Price of Branded & Generic Drugs (in US$), 2006
Figure 5-3: US - Price Comparison of Various Branded & Generic Blood Pressure Drugs (in US$), 2004
Figure 5-4: US - Average Copayments for Generic Drugs, Preferred Branded Drugs & Non-preferred Branded Drugs (in US$), 2000 & 2004
Figure 5-5: US - Sales Value of Drugs Loosing Patent Protection (in Billion US$), 2003-2006
Figure 5-6: US - Comparison of Receipts & Approval of ANDA Applications (in Numbers), 2000–2006
Figure 5-7: US - Share of State & Other Financing in Pharmaceutical Market (%), 2006
Figure 5-8: US - Number of Medicare Beneficiaries (in Million), 1970 to 2030F
Figure 5-9: US - Savings for Medicare from Drugs going Generic (in Billion US$), 2006-2010F
Figure 5-10: US - Population of Age above 65 Years (in Million), 2001-2006
Figure 5-11: US - Relative Per Capita Spending on Drugs by Age Group (%)
Figure 5-12: US - Number of Uninsured People (in Million), 2001-2006E
Figure 5-13: US - Obese* Population in Age Group 20-74 (%), 1960-1962 to 1999-2002**
Figure 5-14: US - Relative Medication Cost due to Obesity, Smoking & Overweight (%)
Figure 5-15: US - Forecast for Breakup of Biogenerics Market by Drugs Type (%), 2016
Figure 5-16: Global - Contract Manufacturing Market (in Billion US$), 2001, 2006E & 2010F
Figure 5-17: US - Relationship between Generic Drugs Price & Number of Generic Competitors (%)
Figure 6-1: US - Population of Age above 65 Years (in Million), 2007-2011F
Figure 6-2: US - Forecast for Number of Uninsured People (in Million), 2007-2011
Figure 6-3: US - Forecast for Pharmaceutical Market (in Billion US$), 2007-2011
Figure 6-4: US - Forecast for Branded Drugs Market (in Billion US$), 2007-2011
Figure 6-5: US - Forecast for Branded Generic Drugs Market (in Billion US$), 2007-2011
Figure 6-6: US - Forecast for Unbranded Generic Drugs Market (in Billion US$), 2007-2011
Figure 6-7: US - Forecast for Penetration of Branded, Branded Generics & Unbranded Generics (%), 2007-2011
Figure 6-8: US - Forecast for Share of Branded, Branded Generics & Unbranded Generics in Growth of Pharmaceutical Market (%), 2006-2011
Figure 8-1: US - Nominal GDP (in Trillion US$), 2001-2006
Figure 8-2: US - Nominal GDP (in Trillion US$), 2007-2011F
Figure 8-3: US - Consumer Price Index (%), 2001-2006
Figure 8-4: US - Consumer Price Index (%), 2007-2011F
Figure 8-5: US - Foreign Direct Investment (in Billion US$), 2005 & 2006
Figure 8-6: US - Population (in Million), 2001-2006
Figure 8-7: US - Population (in Million), 2007-2011F
Figure 8-8: US - Life Expectancy (in Years), 2001-2006E
Figure 8-9: US - Life Expectancy (in Years), 2007-2011F
Figure 8-10: US - Population Breakup by Age Group (%), 2001-2006
Figure 8-11: US - Population Breakup by Age Group (%), 2007-2011F
Figure 8-12: US - Healthcare Spending (in US$ per Head), 2001-2006E
Figure 8-13: US - Healthcare Spending (in US$ per Head), 2007-2011F
Figure 8-14: US - Breakup of Healthcare Payments by Source (%), 2005
Figure 8-15: US - Number of Doctors (per '000 Population), 2001-2006E
Figure 8-16: US - Number of Doctors (per '000 Population), 2007-2011F
Figure 8-17: US - Number of Hospital Beds (per '000 Population), 2001-2006E
Figure 8-18: US - Number of Hospital Beds (per '000 Population), 2007-2011F
Figure 8-19: US - Breakup of Leading Causes of Death (%), 2005
Figure 8-20: US - Number of Deaths due to Leading Causes, 2005
Figure 8-21: US - Forecast for Breakup of Leading Causes of Death (%), 2030
Tables
Table 3-1: US - Retail Pharmaceutical Market by Therapeutic Category (in Million US$), 2006
Table 5-1: US - Actual & Potential Cost Savings from Using Generic Drugs by Therapy Area (in Billion US$), 2005
Table 5-2: US - Estimated & Potential Cost Savings from Using Generic Drugs by Therapy Area (in Billion US$), 2006
Table 5-3: US - Blockbuster Drugs Expected to Lose Exclusivity, 2007-2009
Table 5-4: US - Patent Expiry Dates for Biopharmaceuticals
Table 7-1: US - Sales* of Top 10 Players in Generic Drugs Market (in Million US$), 2005
Table 7-2: US - Number of Prescriptions* of Top 10 Players in Generic Drugs Market (in Million), 2005
Table 7-3: US - Sales** of Top 10 Players in Generic Drugs Market (in Million US$), 2007*
Table 7-4: US - Number of Prescriptions** of Top 10 Players in Generic Drugs Market (in Million), 2007*
Table 7-5: Teva Pharmaceutical Industries Limited - Key Financials (in Million US$), 2004-2006
Table 7-6: Watson Pharmaceuticals, Inc. - Key Financials (in Million US$), 2004-2006
Table 7-7: Sandoz Inc. - Key Financials (in Million US$), 2005 & 2006
Table 7-8: Actavis Group hf - Key Financials (in Million Euro), 2004-2006
